Peer-influenced content. Sources you trust. No registration required. This is HCN.

The New England Journal of MedicineBivalent COVID-19 Vaccines — A Cautionary Tale

The original monovalent vaccines continue to protect against serious disease from the new variants. If SARS-CoV-2 variants evolve to resist the protection against severe disease offered by vaccination or previous infection, then variant-specific vaccines will be needed. Otherwise, this authority recommends we “stop trying to prevent all symptomatic infections in healthy, young people by boosting them with vaccines containing mRNA from strains that might disappear a few months later.”

The Healthcare Communications Network is owned and operated by IQVIA Inc.

Click below to leave this site and continue to IQVIA’s Privacy Choices form